title: IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
abstract: Patients with relapsed lymphoma can be cured with high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). New therapeutic approaches with better cytoreductive capacity are needed for relapsed patients to keep their chance for cure with transplantation. We report 30 patients with relapsed lymphoma, median age 43 years, treated with IIVP salvage regimen consisting of ifosfamide, mesna, idarubicin, and etoposide for 2 or 3 cycles. Seventeen patients had non-Hodgkin lymphoma (NHL) and 13 patients had Hodgkin disease (HD). Fourteen (47%) patients were at their first relapse. Overall response rate was 86.6% (n = 26) with 19 patients (63.3%) achieving complete response. Overall response rate was 92% in patients with HD and 82% in NHL. The most frequent side effects observed were grade III-IV neutropenia (87%) and thrombocytopenia (73%). IIVP regimen is a highly effective salvage therapy for patients with relapsed HD or NHL who are candidates for autologous HSCT. Close follow up is necessary because of the high incidence of grade III-IV hematologic toxicity.
authors.affiliation: Hacettepe University, Institute of Oncology, Ankara, Turkey.
authors.forename: Huseyin
authors.initials: H
authors.lastname: Abali
authors.forename: Basak
authors.initials: B
authors.lastname: Oyan
authors.forename: Yener
authors.initials: Y
authors.lastname: Koc
authors.forename: Ayse
authors.initials: A
authors.lastname: Kars
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Barista
authors.forename: Aysegul
authors.initials: A
authors.lastname: Uner
authors.forename: Alev
authors.initials: A
authors.lastname: Turker
authors.forename: Figen
authors.initials: F
authors.lastname: Demirkazik
authors.forename: Fatma
authors.initials: F
authors.lastname: Tekin
authors.forename: Gulten
authors.initials: G
authors.lastname: Tekuzman
authors.forename: Emin
authors.initials: E
authors.lastname: Kansu
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D007239:Infections / Q000209:etiology; D008223:Lymphoma / Q000188:drug therapy* / Q000601:surgery; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D036102:Peripheral Blood Stem Cell Transplantation; D012008:Recurrence; D012074:Remission Induction; D016879:Salvage Therapy; D013921:Thrombocytopenia / Q000139:chemically induced; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D005047:Etoposide; D007069:Ifosfamide; D015255:Idarubicin